![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, October 02, 2020 12:19:14 PM
"Good Morning
There is talk around here that Trump is to be treated with an experimental inhaler based drug which should stop the infection by protecting the ACE2 receptors and inhibiting SARS-COV-2 from replicating, it apparently has a pending EUA request. I searched the FDA website and i can't find any reference to a inhaled drug that has requested a EUA for CV-19, actually I don't find any information about a pending EUA.. Is there any BCIDP or someone out there who knows which Drug it could be?
My source is credible, but won't give up the name of the drug due to a NDA or similar.. would highly appreciate any information!
thanks for your help!"
Most of the thread is gone now, but but from my recollection, a few people respond to her, including a poster who suggests VIP, and another who links one of the Aviptadil studies (RLF-100). Another poster mentions RLFTF/RLF-100, and FoxMeadowGirl discounts that response as hype or invalid, and that she thinks that the treatment is VIP after looking at the study (apparently not realizing that RLF-100 is the synthetic version). A little later, she asks: "Any FDA "Insider" here that knows the average processing duration of a EUA request for a CV-19 therapeutic these days, for a drug that is not yet approved, cleared, or licensed under sections 505 and 510(k) of the FD&C Act. ?"
Again, who knows. It would be great, though, if true.
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM